Published in Vaccine on June 02, 2006
Flexible architecture of the Streptococcus pyogenes FCT genome region: finally the clue for understanding purulent skin diseases and long-term persistence? J Bacteriol (2006) 0.78
Use of S-[2,3-bispalmitoyiloxy-(2R)-propyl]-R-cysteinyl-amido-monomethoxy polyethylene glycol as an adjuvant improved protective immunity associated with a DNA vaccine encoding Cu,Zn superoxide dismutase of Brucella abortus in mice. Clin Vaccine Immunol (2014) 0.78
Genome Analysis of Streptococcus pyogenes Associated with Pharyngitis and Skin Infections. PLoS One (2016) 0.75
Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood (2010) 3.58
Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology (2010) 1.85
Establishment of a real-time PCR-based approach for accurate quantification of bacterial RNA targets in water, using Salmonella as a model organism. Appl Environ Microbiol (2004) 1.70
The missing link: Bordetella petrii is endowed with both the metabolic versatility of environmental bacteria and virulence traits of pathogenic Bordetellae. BMC Genomics (2008) 1.34
TGF-beta receptor signaling is critical for mucosal IgA responses. J Immunol (2004) 1.13
M protein typing of Thai group A streptococcal isolates by PCR-Restriction fragment length polymorphism analysis. BMC Microbiol (2005) 1.10
Bis-(3',5')-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant. Vaccine (2011) 1.06
Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi. Infect Immun (2007) 1.05
The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. Eur J Immunol (2002) 1.04
Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice. Vaccine (2011) 1.04
The mucosal adjuvant macrophage-activating lipopeptide-2 directly stimulates B lymphocytes via the TLR2 without the need of accessory cells. J Immunol (2005) 1.03
Self-assembled peptide amphiphile micelles containing a cytotoxic T-cell epitope promote a protective immune response in vivo. Adv Mater (2012) 1.01
Vaccines: from empirical development to rational design. PLoS Pathog (2012) 1.01
The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties. Vaccine (2006) 1.01
Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP. PLoS One (2011) 0.98
Immune modulators with defined molecular targets: cornerstone to optimize rational vaccine design. Hum Vaccin (2008) 0.97
Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists. Expert Rev Vaccines (2010) 0.96
Vaccine adjuvants: key tools for innovative vaccine design. Curr Top Med Chem (2013) 0.95
Intranasal vaccination with recombinant P6 protein and adamantylamide dipeptide as mucosal adjuvant confers efficient protection against otitis media and lung infection by nontypeable Haemophilus influenzae. J Infect Dis (2004) 0.95
Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans. J Infect Dis (2003) 0.95
The Toll-like receptor ligand MALP-2 stimulates dendritic cell maturation and modulates proteasome composition and activity. Eur J Immunol (2004) 0.95
Molecular analysis of group B protective surface protein, a new cell surface protective antigen of group B streptococci. Infect Immun (2002) 0.94
Dendritic cell-mediated immune humanization of mice: implications for allogeneic and xenogeneic stem cell transplantation. J Immunol (2014) 0.94
Induction of autoimmune valvulitis in Lewis rats following immunization with peptides from the conserved region of group A streptococcal M protein. J Autoimmun (2003) 0.94
Effects of aging on influenza virus infection dynamics. J Virol (2014) 0.94
Dual role colonization factors connecting Vibrio cholerae's lifestyles in human and aquatic environments open new perspectives for combating infectious diseases. Curr Opin Biotechnol (2008) 0.94
B- and T-cell responses in group a streptococcus M-protein- or Peptide-induced experimental carditis. Infect Immun (2009) 0.94
Lymph node-derived lymphatic endothelial cells express functional costimulatory molecules and impair dendritic cell-induced allogenic T-cell proliferation. FASEB J (2012) 0.93
Bacterial ghosts are an efficient delivery system for DNA vaccines. J Immunol (2004) 0.93
The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant. Clin Vaccine Immunol (2007) 0.90
Multiple-locus variable-number tandem-repeat analysis for clonal identification of Vibrio parahaemolyticus isolates by using capillary electrophoresis. Appl Environ Microbiol (2009) 0.89
Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant. Eur J Immunol (2003) 0.89
The synthetic TLR2 agonist BPPcysMPEG leads to efficient cross-priming against co-administered and linked antigens. Eur J Immunol (2010) 0.89
An SopB-mediated immune escape mechanism of Salmonella enterica can be subverted to optimize the performance of live attenuated vaccine carrier strains. Microbes Infect (2006) 0.88
Intranasal vaccination with recombinant outer membrane protein CD and adamantylamide dipeptide as the mucosal adjuvant enhances pulmonary clearance of Moraxella catarrhalis in an experimental murine model. Infect Immun (2006) 0.88
Regulation of Toll-like receptor-induced chemokine production in murine dendritic cells by mitogen-activated protein kinases. Mol Immunol (2010) 0.88
Cyclic di-nucleotides: new era for small molecules as adjuvants. Microb Biotechnol (2011) 0.87
Efficient immune responses against Intimin and EspB of enterohaemorragic Escherichia coli after intranasal vaccination using the TLR2/6 agonist MALP-2 as adjuvant. Vaccine (2008) 0.87
Intranasal formulations: promising strategy to deliver vaccines. Expert Opin Drug Deliv (2014) 0.87
The member of the cyclic di-nucleotide family bis-(3', 5')-cyclic dimeric inosine monophosphate exerts potent activity as mucosal adjuvant. Vaccine (2010) 0.87
The HIV-1 matrix protein p17 can be efficiently delivered by intranasal route in mice using the TLR 2/6 agonist MALP-2 as mucosal adjuvant. Vaccine (2005) 0.86
An aromatic amino acid auxotrophic mutant of Bordetella bronchiseptica is attenuated and immunogenic in a mouse model of infection. FEMS Microbiol Lett (2003) 0.86
A pegylated derivative of alpha-galactosylceramide exhibits improved biological properties. J Immunol (2007) 0.86
Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant. Vaccine (2005) 0.86
Non-invasive delivery of nanoparticles to hair follicles: a perspective for transcutaneous immunization. Vaccine (2013) 0.85
Purification of hepatitis B surface antigen virus-like particles from recombinant Pichia pastoris and in vivo analysis of their immunogenic properties. J Chromatogr B Analyt Technol Biomed Life Sci (2013) 0.85
Redirection of the immune response to the functional catalytic domain of the cystein proteinase cruzipain improves protective immunity against Trypanosoma cruzi infection. J Infect Dis (2010) 0.85
Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease. Immunol Res (2006) 0.84
Block of death-receptor apoptosis protects mouse cytomegalovirus from macrophages and is a determinant of virulence in immunodeficient hosts. PLoS Pathog (2012) 0.84
Characterization of a B220+ lymphoid cell subpopulation with immune modulatory functions in nasal-associated lymphoid tissues. J Immunol (2005) 0.84
A Toll-like receptor 2/6 agonist reduces allergic airway inflammation in chronic respiratory sensitisation to Timothy grass pollen antigens. Int Arch Allergy Immunol (2009) 0.84
Synthetic peptide AT20 coupled to KLH elicits antibodies against a conserved conformational epitope from a major functional area of the HIV-1 matrix protein p17. Vaccine (2008) 0.83
Dual stimulation of MyD88-dependent Toll-like receptors induces synergistically enhanced production of inflammatory cytokines in murine bone marrow-derived dendritic cells. J Infect Dis (2010) 0.83
A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus. Vaccine (2008) 0.82
Oral vaccine delivery--new strategies and technologies. Curr Drug Deliv (2009) 0.82
Stimulation of long-lasting protection against Streptococcus pyogenes after intranasal vaccination with non adjuvanted fibronectin-binding domain of the SfbI protein. Vaccine (2003) 0.82
A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine. Influenza Other Respir Viruses (2012) 0.82
Intramammary application of non-methylated-CpG oligodeoxynucleotides (CpG) inhibits both local and systemic mammary carcinogenesis in female BALB/c Her-2/neu transgenic mice. Curr Cancer Drug Targets (2008) 0.81
Expression of maturation markers on murine dendritic cells in response to group A streptococcal lipopeptide vaccines. Vaccine (2009) 0.81
Variation in the 16S-23S rRNA intergenic spacer regions in Vibrio parahaemolyticus strains are due to indels nearby their tRNAGlu. FEMS Microbiol Lett (2006) 0.80
Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model. PLoS One (2010) 0.80
Synthesis of a highly pure lipid core peptide based self-adjuvanting triepitopic group A streptococcal vaccine, and subsequent immunological evaluation. J Med Chem (2006) 0.80
Characterization of a novel intracellularly activated gene from Salmonella enterica serovar typhi. Infect Immun (2002) 0.80
Toll-like receptor-2 agonist-allergen coupling efficiently redirects Th2 cell responses and inhibits allergic airway eosinophilia. Am J Respir Cell Mol Biol (2012) 0.80
Toward the development of prophylactic and therapeutic human papillomavirus type-16 lipopeptide vaccines. J Med Chem (2007) 0.79
Lipoamino acid-based adjuvant carrier system: enhanced immunogenicity of group a streptococcal peptide epitopes. J Med Chem (2002) 0.79
Development of a liposaccharide-based delivery system and its application to the design of group A streptococcal vaccines. J Med Chem (2008) 0.79
The Mycoplasma-derived macrophage-activating 2-kilodalton lipopeptide triggers global immune activation on nasal mucosa-associated lymphoid tissues. Infect Immun (2004) 0.79
Development and characterization of attenuated metabolic mutants of Bordetella bronchiseptica for applications in vaccinology. Environ Microbiol (2012) 0.79
Identification of the domains of the fibronectin-binding protein I of Streptococcus pyogenes responsible for adjuvanticity. FEMS Immunol Med Microbiol (2003) 0.79
Toward the development of a synthetic group a streptococcal vaccine of high purity and broad protective coverage. J Med Chem (2004) 0.79
Identification of B- and T-cell epitopes within the fibronectin-binding domain of the SfbI protein of Streptococcus pyogenes. Infect Immun (2003) 0.78
Intranasal immunization with serum opacity factor (SOF) of Streptococcus pyogenes fails to protect mice against lethal mucosal challenge with a heterologous strain. Vaccine (2005) 0.78
Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population. BMC Microbiol (2006) 0.78
Toll-like receptor-mediated adjuvanticity and immunomodulation in dendritic cells: Implications for peptide vaccines. Hum Vaccin (2011) 0.78
Immune modulators with defined molecular targets: cornerstone to optimize rational vaccine design. Adv Exp Med Biol (2009) 0.78
Method for the synthesis of multi-epitopic Streptococcus pyogenes lipopeptide vaccines using native chemical ligation. J Org Chem (2006) 0.78
Immune modulator adamantylamide dipeptide stimulates efficient major histocompatibility complex class I-restricted responses in mice. Clin Vaccine Immunol (2007) 0.77
The toll-like receptor 2/6 ligand MALP-2 reduces the viability of Mycobacterium tuberculosis in murine macrophages. Open Microbiol J (2009) 0.77
HIV pseudovirion vaccine exposing Env "fusion intermediates"-response to immunisation in human CD4/CCR5-transgenic rats. Vaccine (2009) 0.77
Rodents as pre-clinical models for predicting vaccine performance in humans. Expert Rev Vaccines (2015) 0.77
Immunological response to parenteral vaccination with recombinant hepatitis B virus surface antigen virus-like particles expressing Helicobacter pylori KatA epitopes in a murine H. pylori challenge model. Clin Vaccine Immunol (2011) 0.76
The FAI protein of group C streptococci acts as a mucosal adjuvant by the specific targeting and activation of B cells. Int J Med Microbiol (2007) 0.75
Subchronic toxicological evaluation of brea gum (Parkinsonia preacox) as a food additive in BALB/c mice. Drug Chem Toxicol (2009) 0.75
Parenteral and mucosal delivery of a novel multi-epitope M protein-based group A streptococcal vaccine construct: investigation of immunogenicity in mice. Vaccine (2002) 0.75